Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Home Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

Distinct Pharmacokinetics, Tissue Distribution and CNS Penetration of ABI-009 (nab-Sirolimus)

/ Publications

Share the Post

About the Author

Related Posts

Read More
Dave Lennon, PhD
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Aadi Bioscience Announces Closing of Merger with Aerpio Pharmaceuticals and $155M Private Placement
Aadi Bioscience to Participate at the Jefferies “Biotech on the Bay” Summit
Improved tumor penetration, anti-tumor activity, and survival of ABI-009 (nab-sirolimus) versus oral rapamycin and everolimus and investigation of mTOR pathway inhibition
nab-Sirolimus Plus Letrozole in Advanced or Recurrent Endometrioid Endometrial Cancer: A Phase 2, Open-Label, Single-Arm, Prospective, Multicenter Study
Patients With Severe Pulmonary Arterial Hypertension Treated With ABI-009, nab-Sirolimus, an mTOR Inhibitor: Interim Results From a Phase 1 Clinical Trial
UPDATE – Aadi Bioscience Presents Two Abstracts on FYARRO (nab-Sirolimus) at the Annual Meeting of the Connective Tissue Oncology Society (CTOS)

Comments

Comments are closed.